DDInter336 DDInter462
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Celecoxib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) regulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is regulated by {v} (Gene) RAF1
RAF1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Celecoxib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Celecoxib {u} (Compound) causes {v} (Side Effect) Nephritis interstitial
Nephritis interstitial {u} (Side Effect) is caused by {v} (Compound) Cimetidine
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is regulated by {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is downregulated by Dabrafenib (Compound)
Celecoxib (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) regulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is regulated by RAF1 (Gene) and RAF1 (Gene) is bound by Dabrafenib (Compound)
Celecoxib (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Celecoxib (Compound) causes Nephritis interstitial (Side Effect) and Nephritis interstitial (Side Effect) is caused by Cimetidine (Compound) and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is regulated by ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)